Key result
Among healthcare workers who received two doses of the BNT162b2 vaccine, N-specific seroprevalence remained low at 1.59%, while S-specific antibody titers were robust but decreased over time.
Why the study?
Following the early 2021 launch of a vaccination campaign in Japan, researchers sought to re-evaluate seroprevalences of N- and S-specific antibodies in healthcare workers after two doses of the BNT162b2 vaccine.
Does the BNT162b2 vaccine elicit S-specific antibodies in healthcare workers, and how do titers vary by patient characteristics?
Population
2202 HCWs who took two doses of the BNT162b2 vaccine at a frontline hospital in Tokyo
Comparison
N- and S-specific antibody seroprevalence after vaccination across exposure levels and prior COVID-19 status
Authors
Loading...
Low N-seroprevalence persists among vaccinated frontline HCWs; leaves open questions on infection risk and durability of protection.
Cross-Sectional (n=2,202)
No
Does the BNT162b2 vaccine elicit S-specific antibodies in healthcare workers, and how do titers vary by patient characteristics?
The BNT162b2 mRNA vaccine effectively elicits S-specific antibodies in healthcare workers, though titers decrease over time, particularly in elderly individuals.
Igawa et al. (2022) conducted a cross-sectional in SARS-CoV-2 seroprevalence and vaccine response (n=2,202). BNT162b2 vaccination was evaluated on N-specific seroprevalence. Among healthcare workers who received two doses of the BNT162b2 vaccine, N-specific seroprevalence remained low at 1.59%, while S-specific antibody titers were robust but decreased over time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: